Leerink Partners analyst Puneet Souda maintained a Buy rating on Invitae (NYSE:NVTA) on Tuesday, setting a price target of $50, which is approximately 61.71% above the present share price of $30.92.
Souda expects Invitae to post earnings per share (EPS) of -$0.56 for the third quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Moderate Buy rating of shares in Invitae, with an average price target of $38.8.
The analysts price targets range from a high of $50 to a low of $33.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $103.62 million and a net profit of -$112.36 million. The company's market cap is $6.18 billion.
According to TipRanks.com, Leerink Partners analyst Puneet Souda is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.5% and a 66.84% success rate.
Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.